VANDA PHARMACEUTICALS INC. Revenue from Contract with Customer, Excluding Assessed Tax
VANDA PHARMACEUTICALS INC. (VNDA) reported Revenue from Contract with Customer, Excluding Assessed Tax of $50.53 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- VANDA PHARMACEUTICALS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $50.53M, a 3.92% decline year-over-year.
- VANDA PHARMACEUTICALS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $51.72M, a 3.35% increase year-over-year.
- VANDA PHARMACEUTICALS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $57.22M, a 7.58% increase year-over-year.
- VANDA PHARMACEUTICALS INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $56.26M, a 18.06% increase year-over-year.
- VANDA PHARMACEUTICALS INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $216.10M, a 8.72% increase from fiscal 2024.
- VANDA PHARMACEUTICALS INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $198.77M, a 3.18% increase from fiscal 2023.
- VANDA PHARMACEUTICALS INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $192.64M, a 24.27% decline from fiscal 2022.
- VANDA PHARMACEUTICALS INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $254.38M, a 5.32% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $50.53M 10-Q · filed 2026-08-06 | $102.25M 10-Q · filed 2026-08-06 | $159.46M derived: sum of 3 quarters · filed 2026-08-06 | $215.72M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $51.72M 10-Q · filed 2026-05-07 | $108.93M derived: sum of 2 quarters · filed 2026-05-07 | $165.19M derived: sum of 3 quarters · filed 2026-05-07 | $217.78M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $57.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $113.47M derived: sum of 2 quarters · filed 2026-02-12 | $166.06M derived: sum of 3 quarters · filed 2026-08-06 | $216.10M 10-K · filed 2026-02-12 |
| 2025-09-30 | $56.26M 10-Q · filed 2025-10-30 | $108.85M derived: sum of 2 quarters · filed 2026-08-06 | $158.89M 10-Q · filed 2025-10-30 | $212.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $52.59M 10-Q · filed 2026-08-06 | $102.63M 10-Q · filed 2026-08-06 | $155.82M derived: sum of 3 quarters · filed 2026-08-06 | $203.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $50.04M 10-Q · filed 2026-05-07 | $103.23M derived: sum of 2 quarters · filed 2026-05-07 | $150.88M derived: sum of 3 quarters · filed 2026-05-07 | $201.35M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $53.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $100.84M derived: sum of 2 quarters · filed 2026-02-12 | $151.31M derived: sum of 3 quarters · filed 2026-02-12 | $198.77M 10-K · filed 2026-02-12 |
| 2024-09-30 | $47.65M 10-Q · filed 2025-10-30 | $98.13M derived: sum of 2 quarters · filed 2025-10-30 | $145.59M 10-Q · filed 2025-10-30 | $190.86M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $50.47M 10-Q · filed 2025-07-31 | $97.94M 10-Q · filed 2025-07-31 | $143.21M derived: sum of 3 quarters · filed 2026-02-12 | $182.02M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $47.46M 10-Q · filed 2025-05-08 | $92.73M derived: sum of 2 quarters · filed 2026-02-12 | $131.55M derived: sum of 3 quarters · filed 2026-02-12 | $177.60M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $45.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $84.09M derived: sum of 2 quarters · filed 2026-02-12 | $130.14M derived: sum of 3 quarters · filed 2026-02-12 | $192.64M 10-K · filed 2026-02-12 |
| 2023-09-30 | $38.81M 10-Q · filed 2024-11-07 | $84.87M derived: sum of 2 quarters · filed 2024-11-07 | $147.37M 10-Q · filed 2024-11-07 | $211.85M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | $46.06M 10-Q · filed 2024-08-01 | $108.55M 10-Q · filed 2024-08-01 | $173.04M derived: sum of 3 quarters · filed 2025-02-14 | $238.35M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $62.50M 10-Q · filed 2024-05-09 | $126.98M derived: sum of 2 quarters · filed 2025-02-14 | $192.30M derived: sum of 3 quarters · filed 2025-02-14 | $256.69M derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $64.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $129.80M derived: sum of 2 quarters · filed 2025-02-14 | $194.19M derived: sum of 3 quarters · filed 2025-02-14 | $254.38M 10-K · filed 2025-02-14 |
| 2022-09-30 | $65.32M 10-Q · filed 2023-11-09 | $129.71M derived: sum of 2 quarters · filed 2023-11-09 | $189.90M 10-Q · filed 2023-11-09 | $257.92M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-06-30 | $64.39M 10-Q · filed 2023-07-28 | $124.58M 10-Q · filed 2023-07-28 | $192.60M derived: sum of 3 quarters · filed 2024-02-08 | $262.70M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-03-31 | $60.19M 10-Q · filed 2023-05-03 | $128.21M derived: sum of 2 quarters · filed 2024-02-08 | $198.31M derived: sum of 3 quarters · filed 2024-02-08 | $266.20M derived: sum of 4 quarters · filed 2024-02-08 |
| 2021-12-31 | $68.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-08 | $138.11M derived: sum of 2 quarters · filed 2024-02-08 | $206.01M derived: sum of 3 quarters · filed 2024-02-08 | $268.68M 10-K · filed 2024-02-08 |
| 2021-09-30 | $70.09M 10-Q · filed 2022-11-03 | $137.99M derived: sum of 2 quarters · filed 2022-11-03 | $200.66M 10-Q · filed 2022-11-03 | $268.32M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-06-30 | $67.90M 10-Q · filed 2022-08-04 | $130.57M 10-Q · filed 2022-08-04 | $198.22M derived: sum of 3 quarters · filed 2023-02-09 | $258.53M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-03-31 | $62.67M 10-Q · filed 2022-05-06 | $130.32M derived: sum of 2 quarters · filed 2023-02-09 | $190.63M derived: sum of 3 quarters · filed 2023-02-09 | $252.84M derived: sum of 4 quarters · filed 2023-02-09 |
| 2020-12-31 | $67.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $127.96M derived: sum of 2 quarters · filed 2023-02-09 | $190.17M derived: sum of 3 quarters · filed 2023-02-09 | $248.17M 10-K · filed 2023-02-09 |
| 2020-09-30 | $60.31M 10-Q · filed 2021-11-04 | $122.52M derived: sum of 2 quarters · filed 2021-11-04 | $180.51M 10-Q · filed 2021-11-04 | $241.44M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $62.21M 10-Q · filed 2021-07-29 | $120.21M 10-Q · filed 2021-07-29 | $181.14M derived: sum of 3 quarters · filed 2022-02-24 | $240.62M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $58.00M 10-Q · filed 2021-05-06 | $118.93M derived: sum of 2 quarters · filed 2022-02-24 | $178.41M derived: sum of 3 quarters · filed 2022-02-24 | $237.47M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $60.93M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $120.42M derived: sum of 2 quarters · filed 2022-02-24 | $179.47M derived: sum of 3 quarters · filed 2022-02-24 | $227.19M 10-K · filed 2022-02-24 |
| 2019-09-30 | $59.48M 10-Q · filed 2020-10-29 | $118.55M derived: sum of 2 quarters · filed 2020-10-29 | $166.26M 10-Q · filed 2020-10-29 | $219.30M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $59.06M 10-Q · filed 2020-08-06 | $106.77M 10-Q · filed 2020-08-06 | $159.81M derived: sum of 3 quarters · filed 2021-02-11 | $208.95M derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $47.71M 10-Q · filed 2020-05-07 | $100.75M derived: sum of 2 quarters · filed 2021-02-11 | $149.89M derived: sum of 3 quarters · filed 2021-02-11 | $197.24M derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $53.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $102.18M derived: sum of 2 quarters · filed 2021-02-11 | $149.53M derived: sum of 3 quarters · filed 2021-02-11 | $193.12M 10-K · filed 2021-02-11 |
| 2018-09-30 | $49.13M 10-Q · filed 2019-11-07 | $96.48M derived: sum of 2 quarters · filed 2019-11-07 | $140.08M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $47.35M 10-Q · filed 2019-08-01 | $90.94M 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $43.59M 10-Q · filed 2019-05-03 | |||
| 2017-12-31 | $165.08M 10-K · filed 2020-02-26 | |||
| 2016-12-31 | $146.02M 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |